Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into ...
By Deena Beasley (Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing ...
Prime Medicine and Beam Therapeutics had common origins in gene editing. Now they're both pursuing treatments for the same ...
Although cystic fibrosis is a single gene mutation, there are more than 1,000 different ways the CFTR gene can mutate in ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...
The results of this work reveal how an alternative splicing mechanism regulates an essential factor for neuronal identity.
Gene therapy, which promises a possible cure for rare diseases like sickle cell, is losing early investors to higher-reward ...
Clinical Trials Arena on MSN1d
iECURE gene therapy data suggests partial restoration of functional OTCECURE previously announced that the first patient dosed with ECUR-506 for OTC deficiency achieved a complete clinical ...
Beam Therapeutics reported promising Phase 1/2 data for BEAM-302, demonstrating durable gene correction for AATD. See why I ...
Shares of Prime Medicine ( PRME -0.25%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.
Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback